Summary
Regeneron Pharmaceuticals, Inc. reported a strong third quarter of 2023, driven by robust growth in key products like Dupixent and Libtayo, alongside collaboration revenues. Total revenues increased to $3.36 billion, a 14.5% rise year-over-year, with net income reaching $1.01 billion. The company also saw significant growth in its marketable securities portfolio and continued to execute its share repurchase program, returning capital to shareholders. Despite a slight decline in Eylea U.S. net product sales due to increased competition, the approval of Eylea HD in August 2023 provides a significant opportunity for future growth in the ophthalmology market. The company's R&D expenses increased, reflecting ongoing investment in its diverse pipeline, including advancements in oncology and immunology. Regeneron maintains a solid financial position with substantial cash and marketable securities, providing flexibility for future investments and strategic initiatives.
Financial Highlights
46 data points| Revenue | $3.36B |
| R&D Expenses | $1.08B |
| SG&A Expenses | $640.50M |
| Operating Expenses | $2.25B |
| Operating Income | $1.11B |
| Interest Expense | $17.80M |
| Net Income | $1.01B |
| EPS (Basic) | $9.48 |
| EPS (Diluted) | $8.89 |
| Shares Outstanding (Basic) | 106.30M |
| Shares Outstanding (Diluted) | 113.40M |
Key Highlights
- 1Total revenues increased by 14.5% to $3.36 billion in Q3 2023 compared to Q3 2022.
- 2Net income rose to $1.01 billion ($8.89 diluted EPS) in Q3 2023, compared to $1.32 billion ($11.66 diluted EPS) in Q3 2022, reflecting increased revenues offset by higher R&D and SG&A expenses.
- 3Dupixent revenues grew significantly, with Sanofi collaboration revenue up 50% year-over-year, driven by strong performance in immunology and inflammation.
- 4EYLEA HD received FDA approval in August 2023, positioning it for future growth in the ophthalmology market, despite a slight decline in Eylea U.S. sales.
- 5The company's R&D expenses increased by 18% year-over-year to $1.08 billion, reflecting continued investment in its pipeline, including $100 million for an Alnylam development milestone.
- 6Regeneron repurchased $507.1 million of its common stock in Q3 2023 under its authorized repurchase program, demonstrating a commitment to returning capital to shareholders.
- 7The company ended the quarter with a strong liquidity position, holding $2.15 billion in cash and cash equivalents and $13.54 billion in marketable securities.